Revisiting AGuIX Radiosensitization in a Lung Tumor Model with pH Targeting

AGuIX nanoparticles are gadolinium (Gd)-based, sub-5 nm nanoparticles designed for radiosensitization and MRI contrast enhancement. The high atomic number of Gd (Z = 64) enables efficient X-ray absorption and dose deposition within tumors, with tumor accumulation facilitated by the enhanced permeability and retention effect. Previous clinical trials have provided preliminary evidence for the safety and potential therapeutic benefit of intravenous AGuIX in patients with cervical cancer and brain metastases. To improve tumor specificity, we conjugated AGuIX with a pH-low insertion peptide (pHLIP-AGuIX), which targets the acidic tumor microenvironment through pH-dependent membrane insertion. In vitro experiments were performed with cultured A549 human lung adenocarcinoma cells at pH 6.2 (tumor-like) and pH 7.4 (physiologic) conditions. In vivo, mice bearing subcutaneously implanted A549 tumors received 10 Gy X-ray irradiation with or without unconjugated AGuIX or pHLIP-AGuIX pretreatment (300 mg/kg; n = 7 mice/group). Colony formation assays and mass spectroscopy analysis revealed that conjugation of the pHLIP peptide to AGuIX increased intracellular Gd levels approximately 18-fold under acidic conditions compared to unconjugated AGuIX, but without significantly altering cell survival at the tested concentration (0.17 mM). In vivo, all ir-radiated groups exhibited significant tumor growth delay compared to controls (P < 0.01), but no additional radiosensitization was observed in the nanoparticle-treated cohorts, despite detectable Gd tumor accumulation. MRI T1 mapping demonstrated shortened T1 relaxation times following AGuIX administration, with greater reduction following pHLIP-AGuIX injection. These findings suggest that pHLIP conjugation improves Gd uptake and MRI visibility but does not enhance therapeutic efficacy under current conditions. Departing from previous work, this study used a simpler covalent bond to conjugate pHLIP to AGuIX rather than a disulfide bridge, which may explain the decreased efficacy. Reintroducing the disulfide linkage might be critical, as it allows the nanoparticle cargo to break free from its membrane-bound anchor and reach the nucleus.

Authors

Publication Details

Journal
Preprints.org
Published
2026-11-18
DOI
https://doi.org/10.20944/preprints202611.1937.v1
Primary Topic
Radiation Therapy and Dosimetry
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Revisiting AGuIX Radiosensitization in a Lung Tumor Model with pH Targeting

Guillem Pratx, Jessica Wen, Yuwei Xue, Wu Liu
Preprints.org
Radiation Therapy and Dosimetry
preprint

Revisiting AGuIX Radiosensitization in a Lung Tumor Model with pH Targeting

Guillem Pratx, Jessica Wen, Yuwei Xue, Wu Liu
preprint en

Abstract

AGuIX nanoparticles are gadolinium (Gd)-based, sub-5 nm nanoparticles designed for radiosensitization and MRI contrast enhancement. The high atomic number of Gd (Z = 64) enables efficient X-ray absorption and dose deposition within tumors, with tumor accumulation facilitated by the enhanced permeability and retention effect. Previous clinical trials have provided preliminary evidence for the safety and potential therapeutic benefit of intravenous AGuIX in patients with cervical cancer and brain metastases. To improve tumor specificity, we conjugated AGuIX with a pH-low insertion peptide (pHLIP-AGuIX), which targets the acidic tumor microenvironment through pH-dependent membrane insertion. In vitro experiments were performed with cultured A549 human lung adenocarcinoma cells at pH 6.2 (tumor-like) and pH 7.4 (physiologic) conditions. In vivo, mice bearing subcutaneously implanted A549 tumors received 10 Gy X-ray irradiation with or without unconjugated AGuIX or pHLIP-AGuIX pretreatment (300 mg/kg; n = 7 mice/group). Colony formation assays and mass spectroscopy analysis revealed that conjugation of the pHLIP peptide to AGuIX increased intracellular Gd levels approximately 18-fold under acidic conditions compared to unconjugated AGuIX, but without significantly altering cell survival at the tested concentration (0.17 mM). In vivo, all ir-radiated groups exhibited significant tumor growth delay compared to controls (P < 0.01), but no additional radiosensitization was observed in the nanoparticle-treated cohorts, despite detectable Gd tumor accumulation. MRI T1 mapping demonstrated shortened T1 relaxation times following AGuIX administration, with greater reduction following pHLIP-AGuIX injection. These findings suggest that pHLIP conjugation improves Gd uptake and MRI visibility but does not enhance therapeutic efficacy under current conditions. Departing from previous work, this study used a simpler covalent bond to conjugate pHLIP to AGuIX rather than a disulfide bridge, which may explain the decreased efficacy. Reintroducing the disulfide linkage might be critical, as it allows the nanoparticle cargo to break free from its membrane-bound anchor and reach the nucleus.

Preprints.org
Radiation Therapy and Dosimetry
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon